Arcus Biosciences (RCUS) Tops Q3 EPS by 19c

Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($0.94), $0.19 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $32 million versus the consensus estimate of $27.57 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Carnival shares drop despite earnings beat on weak guidance
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus